Newsroom

Discover our latest news

December 19, 2019:
Achillion Shareholders Approve Agreement to be Acquired by Alexion

December 09, 2019:
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

November 19, 2019:
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

DOWNLOADS ON DEMAND

FACTOR D EXPLAINED – Whiteboard Animations

Module 1
"What is the complement system?"
Download Now

Module 2
"What is the Alternative Pathway?"
Download Now

Module 3
"What is PNH?"
Download Now

Module 4
"What is C3G?"
Download Now

Module 5
"Achillion Pharmaceuticals"
Download Now

Modules 1-5: FACTOR D - A Trigger Point for Complement Activity by Achillion Pharmaceuticals
Download Now

COMPLEMENT SYMPOSIUM HOSTED BY ACHILLION

Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting,
December 6, 2015.

Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.

Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.

Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases,
including PNH.